Kirsten Karberg
Overview
Explore the profile of Kirsten Karberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strunz P, Risser L, Englbrecht M, Witte T, Froehlich M, Schmalzing M, et al.
Front Immunol
. 2024 Sep;
15:1445680.
PMID: 39238648
Background: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is...
2.
Strunz P, Englbrecht M, Risser L, Witte T, Froehlich M, Schmalzing M, et al.
Rheumatol Int
. 2024 Aug;
44(10):2057-2066.
PMID: 39136784
In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe...
3.
Strunz P, Englbrecht M, Risser L, Witte T, Froehlich M, Schmalzing M, et al.
Front Immunol
. 2024 Jun;
15:1395968.
PMID: 38846940
Objective: Treatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs;...
4.
Albrecht K, Thiele K, Alexander T, Aringer M, Eidner T, Henes J, et al.
Z Rheumatol
. 2024 Apr;
83(8):666-674.
PMID: 38568444
In the National database (NDB) of the German regional collaborative arthritis centres, annual data on the rheumatological care of patients with inflammatory rheumatic diseases have been collected since 1993. This...
5.
Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, et al.
Lancet
. 2024 Feb;
403(10429):850-859.
PMID: 38364841
Background: Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain...
6.
Dreher M, Witte T, Hoeper K, Assmann G, Proft F, Poddubnyy D, et al.
Ann Rheum Dis
. 2023 Oct;
83(2):184-193.
PMID: 37890976
Objectives: Early diagnosis of inflammatory arthritis is critical to prevent joint damage and functional incapacities. However, the discrepancy between recommendations of early diagnosis and reality is remarkable. The Rheuma-VOR study...
7.
Kleinert S, Schuch F, Rapp P, Ronneberger M, Wendler J, Sternad P, et al.
Rheumatol Int
. 2023 Oct;
44(4):653-661.
PMID: 37805981
The categorization of axial spondyloarthritis (axSpA) into radiographic (r-axSpA) and non-radiographic (nr-axSpA) subtypes is important in clinical trials but may be of less value in clinical practice. This exploratory cross-sectional,...
8.
Braun J, Karberg K
Z Rheumatol
. 2023 Sep;
83(8):650-660.
PMID: 37707569
Rheumatic and musculoskeletal diseases (RMD) include various diseases with sometimes rather different symptoms, some of which are locally confined and others show systemic features. Autoimmune phenomena, such as those occurring...
9.
Callhoff J, Feuchtenberger M, Karberg K, Kiltz U, Aringer M, Baraliakos X, et al.
Z Rheumatol
. 2023 Jun;
82(6):508-516.
PMID: 37280334
The national database (NDB) of the German regional collaborative rheumatology centers was switched to the RheMIT documentation software last year. Rheumatology centers that already use RheMIT for care contracts or...
10.
Braun J, Mairinger T, Kaschke O, Behrendt K, Ramsbacher J, Karberg K
RMD Open
. 2023 May;
9(2).
PMID: 37164447
A 68-year-old woman presented with bilateral swelling of the salivary glands, sicca symptoms of eyes and mouth, itching, fatigue and weight gain of about 5 kg in the last 2-3...